Trial of Immunotherapy in HIV Patients: Our Experience with the Immuno-Modulator Dithiodinicotinic Acid (CPDS) in 34 Congolese Patients

Authors

  • Ndarabu

Keywords:

Abstract

Background: ART had substantially improved the quality of life of PLWHA, but cannot alone eradicate the HIV reservoirs neither fully restoring the impaired immune system functioning. Its life long duration is associated with the risk of resistant strain emerging and metabolic disorders, mainly in resources constrained settings. Objectives: To study the impact of an Immune modulator in PLWHA. Method: In this prospective study, we used a immune modulator, 6,6’-dithiodinicotinic acid (CPDS) in 34 Congolese PLWHA (study group) for a 2 years period opportunely compared to 60 PLWHA who underwent ARV (control group). Data were analyzed using Mixed models using IBM SPSS Statistics v. 20. Results: Both groups were comparable at the starting point. Globally, we observed a similar evolution of weight and the CD4 counts in both groups during the first 12 months period of study with a gradual increase and a peak by the 6th month. Immunotherapy group displayed higher values of CD4, CD8 lymphocytes and the CD4/CD8 ratio. There was no significant difference between risks of dying between both groups. RR: 0.953 {0.67; 1.35} neither in the rate of hospitalization. Conclusion: This study suggests the benefit of immunotherapy in treatment of PLWHA and its possible association to ART.

How to Cite

Trial of Immunotherapy in HIV Patients: Our Experience with the Immuno-Modulator Dithiodinicotinic Acid (CPDS) in 34 Congolese Patients. (2017). Global Journal of Medical Research, 17(5), 19-26. https://medicalresearchjournal.org/index.php/GJMR/article/view/

References

C. Hoffman, J. Rockstroh (2015) HIV 2015/16, www. 20.

(2012) MSF, Unité d'analyse et de Plaidoyer, Juillet 2012 [Access on Jan 2016].

(2014) Enquête Démographique et de Santé en République Démocratique du Congo.

Musumari PM, Wouters E, Kayembe PK (2014) Food Insecurity Is Associated with Increased Risk of Non- Adherence to Antiretroviral Therapy among HIV- Infected Adults in the Democratic Republic of Congo: A Cross-Sectional Study. 9(1), e85327. https://doi.org/10.1371/journal.pone.0085327

Sunguya BF, Urassa DP, Yasuoka J (2015) The Role of Nutrition Training for Health Workers in Addressing Poor Feeding Practices and Undernutrition Among HIV-Positive Children. (2), 113-150.

Fida FAO, Pam (2015) L'état de l'insécurité alimentaire dans le monde 2015. Objectifs internationaux 2015 de réduction de la faim: des progrès inégaux.

Kalichman SC, Pellowski JA, Hernandez D (2015) Alcohol Use and Food Insecurity in HIV Disease Management. (2), 45-57.

Ue Lahuerta M, Hoffman S (2013) The Problem of Late ART initiation in Sub-Saharan Africa: A Transient Aspect of Scale-up or a Longterm Phenomenon?. 24(1), 359-83.

N. Conolly, S. Ridler, C. Rinaldo (2005) Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches. 7(3), 168-180.

M. Gontran, L. Jerome, A. Yvonne (2009) Effects of IM28 on HIV-1 and Metabolic Disorders-induced Highly Active Antiretroviral Therapy in Gabonese Patients. 1, 76-81.

A. Ndungu, ZW, E. Kuria, N. Gikonyo, D. Mbithe (2017) Efficacy of amaranth grain consumption on CD4 count and morbidity patterns among adults living with HIV in Nyeri, Kenya. 9(4), 81-88.

Burini RC, Moreto F, Yong-Ming Y (2015) HIV-Positive Patients Respond to Dietary Supplementation with Cysteine or Glutamine. (2), 245-64.

Dh1 Chang, K. Osman, J. Connolly (2005) Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients, J Exp Med. 201(9), 1503-1517.

M. Gontran, L. Jerome, A. Yvonne (2009) Effects of IM28 on HIV-1 and Metabolic Disordersinduced Highly Active Antiretroviral Therapy in Gabonese Patients. 1, 76-081. https://doi.org/10.4172/jaa.1000011

D. Grassetti (1986) The antimetastatic and tumor growth retarding effects of sulfur containing analogs of nicotinamide. 31, 187-195.

D. Grassetti, C. Moro (2002) Grassetti DR, Moro C, Method of immunomodulation using thione-forming disulfides. 463.

D. Grassetti (1970) Effect of 6,6-ditiodinicotinic acid on the dissemination of Ehrlich ascites tumor. 5258(228), 282-283.

A. Ndarabu, D. Shada, T. Katako, D. Mbuyi, A. Lukusa, R. Ngalamulume, L. Tshilolo (2017) HIV status of Children Born to Mothers with HIV infection in a semi urban area in DR Congo: an experience from Monkole Hospital Center. (2).

S. D'Ancona, G. Magnolfi, G. Toffoli (1984) D'Ancona S, Magnolfi G, Toffoli G et al. variations of growth, adhesion.

S. Michael, Saag (2001) The role of immunotherapy in the treatment of HIV. (suppl 2), S1-S3.

Smith KA (2001) To cure chronic HIV infection, a new therapeutic strategy is needed. 13, 617-24.

Kokot Całyniuk B, Nowakowska-Zajdel E, et al.Nutrition, Food Patients, Health of HIV Infected People (2015) Nutrition and Food in AIDS Patients. 2, 131-46.

Michael Saag (2001) Saag MS, The impact of highly active antiretroviral therapy on HIV-specific immune function, AIDS 2001, 15 (suppl 2): S4-S40. 15(suppl 2), S4-S10. https://doi.org/10.1097/00002030-200102002-00002

G. Bahr1, De La Tribonnière, X. Darcissac, E. (2003) Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment. 51, 1377-88.

Bart PA, Pantaleo G (2006) Immune-based interventions in HIV infection: doing the right studies, getting the right answers, AIDS 2006. 20, 617-618.

Ann S, Gareth H, Mark N (2003) Interleukin-2-associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active Legends antiretroviral therapy. 17(4), 628-629.

Mavoungou D, Poaty-Mavoungou V, Akoume M-Y (2005) Inhibition of human immunodeficiency virus type-1 (HIV-1) glycoprotein-mediated cell-cell fusion by immunor (IM28). 2(1), 9. https://doi.org/10.1186/1743-422x-2-9

Trial of Immunotherapy in HIV Patients: Our Experience with the Immuno-Modulator Dithiodinicotinic Acid (CPDS) in 34 Congolese Patients

Published

2017-03-06

How to Cite

Trial of Immunotherapy in HIV Patients: Our Experience with the Immuno-Modulator Dithiodinicotinic Acid (CPDS) in 34 Congolese Patients. (2017). Global Journal of Medical Research, 17(5), 19-26. https://medicalresearchjournal.org/index.php/GJMR/article/view/